Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME
Axel Bex(The Royal Free Hospital), John Haanen, Bertrand Tombal(Cliniques Universitaires Saint-Luc), Sandra Collette(University of Turin), Sylvie Rottey(Ghent University Hospital), T. Powles, Pilar Laguna(Istanbul Medipol University), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Harm van Melick, Peter F.A. Mulders(Radboud University Nijmegen), Lori Wood(Dalhousie University), Laurence Collette(GlaxoSmithKline (Belgium)), Patricia M.M.B. Soetekouw(Radboud University Nijmegen), R. Van Velthoven, Jean-Baptiste Lattouf, Igle J. de Jong(University of Groningen), Michael Jewett(Cancer Genomics Centre), John Wagstaff(Maastricht University Medical Centre)
Cited by 7
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k